Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: impact of clinicopathological factors and indirect comparison between treatment strategies
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: impact of clinicopathological factors and indirect comparison between treatment strategies
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF CANCER
Volume -, Issue -, Pages 113404
Publisher
Elsevier BV
Online
2023-10-27
DOI
10.1016/j.ejca.2023.113404
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Neoadjuvant immunotherapy for advanced, resectable non–small cell lung cancer: A systematic review and meta‐analysis
- (2023) Yajing Wu et al. CANCER
- Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study.
- (2023) Shun Lu et al. JOURNAL OF CLINICAL ONCOLOGY
- Early-Stage Lung Cancer: Using Circulating Tumor DNA to Get Personal
- (2023) Christine M. Bestvina et al. JOURNAL OF CLINICAL ONCOLOGY
- Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
- (2023) Heather Wakelee et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy
- (2023) Suzanne L. Topalian et al. CANCER CELL
- Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges
- (2023) Giannis Mountzios et al. Nature Reviews Clinical Oncology
- Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer
- (2023) Mariano Provencio et al. NEW ENGLAND JOURNAL OF MEDICINE
- Egress of resident memory T cells from tissue with neoadjuvant immunotherapy: Implications for systemic anti-tumor immunity
- (2023) Magdalena A Rainey et al. ORAL ONCOLOGY
- Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
- (2022) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial
- (2022) Virginie Westeel et al. LANCET ONCOLOGY
- 930MO PD-L1 expression and outcomes of pembrolizumab and placebo in completely resected stage IB-IIIA NSCLC: Subgroup analysis of PEARLS/KEYNOTE-091
- (2022) S. Peters et al. ANNALS OF ONCOLOGY
- Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
- (2022) Mary O’Brien et al. LANCET ONCOLOGY
- Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)
- (2022) Marie Wislez et al. Journal for ImmunoTherapy of Cancer
- Brief report: Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC – an update from the PACIFIC trial
- (2021) Corinne Faivre-Finn et al. Journal of Thoracic Oncology
- Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
- (2021) Enriqueta Felip et al. LANCET
- Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial
- (2020) Catherine A Shu et al. LANCET ONCOLOGY
- 1215O - SC Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): Results from the phase II PRINCEPS trial
- (2020) B. Besse et al. ANNALS OF ONCOLOGY
- Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
- (2020) Mariano Provencio et al. LANCET ONCOLOGY
- Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade
- (2020) Qu Zhang et al. Cancer Discovery
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data
- (2014) LANCET
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
- Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
- (2008) Jean-Pierre Pignon et al. JOURNAL OF CLINICAL ONCOLOGY
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
- (2008) Gordon H Guyatt et al. BMJ-British Medical Journal
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation